Home>Topics>Companies>Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
  1. Sanofi- Regeneron drug tames eczema in study

    Headlines

    Wed, 9 Jul 2014

    PARIS/NEW YORK, July 9 (Reuters) - An experimental drug from Sanofi and Regeneron Pharmaceuticals Inc significantly reduced skin lesions and itching in adult patients with atopic dermatitis, a chronic form of eczema that is poorly

  2. Sanofi Is Buying Shares Of Regeneron - You Should Too

    Headlines

    Wed, 9 Jul 2014

    Jonathan Koss : Regeneron Pharmaceuticals , Inc . ( REGN ) is a U.S ..... FDA approved Regeneron 's Eylea , a treatment for ..... following two years, Regeneron 's share price ..... predicted success of Eylea and its high sales

  3. Sanofi raises stake in Regeneron to 22.5 percent from 20.5 percent

    Headlines

    Tue, 1 Jul 2014

    July 1 (Reuters) - French drugmaker Sanofi SA will raise its stake in Regeneron Pharmaceuticals Inc to 22.5 percent, Sanofi said in a U.S. regulatory filing Tuesday, as part of an agreement between...

  4. CHMP recommends label expansion for Eylea

    Headlines

    Fri, 27 Jun 2014

    Agency (EMA) approve Regeneron Pharmaceuticals ' ( REGN ) Eylea ( aflibercept ) injection ..... macular edema (DME). Eylea is currently approved ..... occlusion (CRVO). Regeneron and Bayer Healthcare ..... global development of Eylea . Regeneron has exclusive

  5. BRIEF-U.S. judge rejects Merus bid to dismiss Regeneron patent lawsuit

    Headlines

    Thu, 19 Jun 2014

    June 19 (Reuters) - Regeneron Pharmaceuticals Inc : * U.S. judge denies merus bv's bid to dismiss Regeneron Pharmaceuticals inc 's

  6. Positive Phase 3 results for sarilumab

    Headlines

    Thu, 12 Jun 2014

    interrupts the resultant cytokine-mediated inflammatory signalling. Sarilumab is being co-developed by Regeneron Pharmaceuticals ( REGN -0.2% ) and Sanofi ( SNY ). Post your comment!

  7. Eylea label expansion application submitted to EMA

    Headlines

    Wed, 11 Jun 2014

    Regeneron Pharmaceuticals ( REGN ) reports that collaboration ..... European Union for Eylea (aflibercept) for ..... has also approved Eylea for wet AMD and Macular ..... Diabetic Macular Edema. Regeneron has exclusive rights to Eylea in the U.S. Bayer

  8. New Morningstar Analyst Report for Roche Holding AG

    Stock Reports

    Tue, 3 Jun 2014

    several significant drugs in the interim. Blockbuster eye disease drug Lucentis is witnessing intense competition from Regeneron 's Eylea , and while we expect the drug to hold its own, we doubt Lucentis will continue to serve as the growth driver it has been

  9. Eylea's 1Q U.S. Sales Soft; Regeneron's Strong Pipeline Progress Continues; Maintaining FVE

    Commentary

    Thu, 8 May 2014

    Regeneron reported first-quarter results that ..... disappointing due to sluggish sales of Eylea in the U.S. However, the company ..... first quarter of 2013. Revenue included Eylea U.S. net product sales of $359 million ..... market share trends. Rest-of-world Eylea sales, as reported by partner Bayer

  10. FDA probes cognitive impact of new cholesterol drugs

    Headlines

    Fri, 7 Mar 2014

    (Reuters) - The Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said...

« Prev12345Next »
Content Partners